The Motley Fool
09 Jun 2026, 01:13 UTC · 20w ago
Why Eli Lilly Stock Climbed to a New All-Time High Today
Impact · against what's priced in
Eli Lilly receives a positive catalyst from Phase 3 retatrutide results showing 28% weight loss and comorbidity benefits, strengthening its moat in the obesity market. Conversely, Zealand Pharma faces a negative catalyst due to safety and tolerability failures in its experimental obesity drug.
- ZLDPF−0.70
No priced-in read yet
- In context
The reporting of discouraging safety and tolerability results for its experimental obesity drug creates a significant clinical setback.
Read from the article alone
